WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical firm advancing focused protein degradation to ship novel small molecule protein degrader medicines, will report third quarter 2022 monetary outcomes on November 3, 2022 and can host a convention name at 8:30 a.m. ET that day.
Kymera Therapeutics additionally introduced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will take part in Fireside Chat webcasts on the following upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA on November 9, 2022, at 9:50 a.m. PT
- Stifel 2022 Healthcare Conference in New York, NY, on November 15, 2022, at 3:35 p.m. ET
- Piper Sandler 34th Annual Healthcare Conference in New York, NY, on November 29 – December 1, 2022, date/time TBD
- Bank of America 2022 Biotech SMID Cap Conference in Boston, MA, on December 7, 2022, at 3:30 p.m. ET
To entry the November 3 convention name through telephone, please dial 888-672-2415 (U.S.) or +1-646-307-1952 (International) and ask to be a part of the Kymera Therapeutics name. A reside webcast of the occasion will likely be accessible underneath “Events and Presentations” within the Investors part of the Company’s web site at www.kymeratx.com. A replay of the webcast will likely be archived and accessible for one month following the occasion.
About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a biopharmaceutical firm pioneering the sector of focused protein degradation, a transformative strategy to tackle illness targets and pathways inaccessible with standard therapeutics. Kymera’s Pegasus platform is a robust drug discovery engine, advancing novel small molecule therapies that harness the physique’s innate protein recycling equipment to degrade dysregulated, disease-causing proteins. With a spotlight on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutics designed to tackle essentially the most intractable pathways and supply new therapies for sufferers. Kymera’s preliminary applications goal IRAK4, IRAKIMiD, and STAT3 throughout the IL-1R/TLR or JAK/STAT pathways, offering the chance to deal with sufferers with a broad vary of immune-inflammatory ailments, hematologic malignancies, and stable tumors. For extra data, go to www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology firm by Fierce Biotech and has been acknowledged by the Boston Business Journal as certainly one of Boston’s “Best Places to Work.” For extra details about our folks, science, and pipeline, please go to www.kymeratx.com or observe us on Twitter or LinkedIn.
Investor Contact:
Bruce Jacobs
Chief Financial Officer
traders@kymeratx.com
857-285-5300
Chris Brinzey
Managing Director, Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media Contact:
Todd Cooper
Senior Vice President, Corporate Affairs
media@kymeratx.com
857-285-5300
